





IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A compound ~~Diarylalkene derivatives or diarylalkane derivatives of the following general formula (1), (2), (3) or (4) (1) or (2), or a~~  
 pharmaceutically acceptable salts salt thereof:



wherein A represents ~~CH=CH, CH<sub>2</sub>-CH<sub>2</sub>, S, CH<sub>2</sub>-S, S-CH<sub>2</sub>, O, CH<sub>2</sub>-O, O-CH<sub>2</sub>, N(R<sup>17</sup>)-CH<sub>2</sub>, CH<sub>2</sub>-N(R<sup>17</sup>), CH=CH-CH<sub>2</sub>, CH<sub>2</sub>-CH=CH, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>, N(R<sup>17</sup>)-(CO), (CO)-N(R<sup>17</sup>), (CO), (SO) or C(R<sup>18</sup>R<sup>19</sup>)~~ wherein R<sup>17</sup> represents H, a lower alkyl or an aryl, and R<sup>18</sup> and R<sup>19</sup> are each independently selected from the group consisting of H, a lower alkyl, an aryl and C(O)OR<sup>15</sup> wherein R<sup>15</sup> represents a lower alkyl or an aryl -S-;

a, b, c and d are each selected from the group consisting of CR<sup>1</sup> and CR<sup>2</sup>;

or one of a, b, c and d is N;

R<sup>1</sup>, R<sup>2</sup> and R<sup>4</sup> each independently represent H, a halogen, -CF<sub>3</sub>, -OR<sup>14</sup>, -COR<sup>14</sup>, -SR<sup>14</sup>, -S(O)R<sup>15</sup>, -N(R<sup>14</sup>)<sub>2</sub>, -NO<sub>2</sub>, -OC(O)R<sup>14</sup>, -CO<sub>2</sub>R<sup>14</sup>, -OCO<sub>2</sub>R<sup>14</sup>, -CN, -NR<sup>14</sup>COOR<sup>15</sup>, -SR<sup>15</sup>C(O)OR<sup>15</sup> or -SR<sup>15</sup>N(R<sup>16</sup>)<sub>2</sub> wherein R<sup>14</sup> represents H, a lower alkyl, an aryl or an aryl-lower alkyl group, R<sup>15</sup> represents a lower alkyl or an aryl group, R<sup>16</sup> is independently selected from the group consisting of H and -C(O)OR<sup>15</sup>, and t represents 1 or 2;

R<sup>3</sup> represents H;

V-W represents C=C, CH-CH, CH-N or N-CH C=C;

~~Z is selected from the group consisting of C, CH and N (with the proviso that when Z is C, the bond represented by a dotted line represents a double bond and when Z is CH or N, the bond represented by the dotted line represents a single bond;~~

n represents 0 to 3;

R<sup>5</sup> and R<sup>6</sup> each independently represent H, a halogen, -CF<sub>3</sub>, a lower alkyl or an aryl; or R<sup>5</sup> and R<sup>6</sup> together form =O or =S;

Y<sup>1</sup> represents O or S;

B represents NR<sup>17a</sup>, -NR<sup>17a</sup>(CH<sub>2</sub>)<sub>v</sub>CHR<sup>21</sup>-, -(CH<sub>2</sub>)<sub>v</sub>CHR<sup>21</sup>- wherein v represents 0 to 3, R<sup>17a</sup> represents H, a lower alkyl or an aryl, R<sup>21</sup> represents H, a lower alkyl, an aryl, a

hydroxyl-lower alkyl,  $-\text{CH}_2\text{SH}$ ,  $-\text{CH}_2\text{CH}_2\text{SCH}_3$ ,  $-\text{CH}_2(\text{CO})\text{NH}_2$ ,  $-\text{CH}_2\text{CH}_2(\text{CO})\text{NH}_2$ ,  
 $-(\text{CH}_2)_w\text{COOR}^{29}$ ,  $-(\text{CH}_2)_w\text{NR}^{29}\text{R}^{30}$  wherein  $\text{R}^{29}$  and  $\text{R}^{30}$  each independently represent  
hydrogen atom or a lower alkyl group, and  $w$  represents 0 to 4,  $-(\text{CH}_2)_3\text{NHC}(\text{NH}_2)=\text{NH}$ ,  
benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazoymethyl;


$G$  represents  $-(\text{CO})-$ ,  $-(\text{SO})-$ ,  $-(\text{SO}_2)-$  or a covalent bond;

$m$  represents 0 to 6;

$\text{Y}^2$  represents C or S;

$p$  and  $q$  are each independently selected from the group consisting of 1, 2 and 3;

$\text{R}^7$  and  $\text{R}^8$  each independently represent H, a lower alkyl, an aryl,  $-(\text{CO})\text{R}^{18a}$ ,  
 $-(\text{CS})\text{R}^{18a}$ ,  $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$ ,  $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$  wherein  $\text{R}^{18a}$  represents H, a lower alkyl, an  
aryl or a cycloalkyl group which may have a hetero atom in the ring,  $\text{R}^{19a}$  represents H, a  
lower alkyl or an aryl; or  $\text{R}^{18a}$  and  $\text{R}^{19a}$  together form a cycloalkyl which may have a halogen,  
 $-\text{CF}_3$ , a lower alkyl or an aryl as a substituent,  $-(\text{CO})\text{OR}^{20}$  or  $-(\text{CS})\text{OR}^{20}$  wherein  $\text{R}^{20}$   
represents an alkyl group having 1 to 12 carbon atoms, an aryl group or a cycloalkyl group  
which may have a hetero atom in the ring, or a group of the following general formula (5):



wherein  $\text{Y}^4$  and  $\text{Y}^3$  each represent O or S;  $s$  represents 0 to 6;

$E$  represents  $\text{NR}^{22}$  or  $\text{CHR}^{23}$  wherein  $\text{R}^{22}$  represents H, a lower alkyl or aryl; and  $\text{R}^{23}$   
represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl,  $-\text{CH}_2\text{SH}$ ,  $-\text{CH}_2\text{CH}_2\text{SCH}_3$ ,

$-\text{CH}_2(\text{CO})\text{NH}_2$ ,  $-\text{CH}_2\text{CH}_2(\text{CO})\text{NH}_2$ ,  $-\text{CH}_2\text{COOH}$ ,  $-\text{CH}_2\text{CH}_2\text{COOH}$ ,  $-(\text{CH}_2)_4\text{NH}_2$ ,  
 $-(\text{CH}_2)_3\text{NHC}(\text{NH}_2)=\text{NH}$ , benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl;

$\text{R}^{24}$  represents H, a lower alkyl or an aryl;


$\text{R}^{25}$  represents H, a lower alkyl, an aryl,  $-\text{OR}^{18a}$ ,  $-(\text{CO})\text{R}^{18a}$ ,  $-(\text{CS})\text{R}^{18a}$ ,  
 $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$ ,  $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$ ,  $-(\text{CO})\text{OR}^{20}$  or  $-(\text{CS})\text{OR}^{20}$  wherein  $\text{R}^{18a}$ ,  $\text{R}^{19a}$  and  $\text{R}^{20}$  are  
as defined above,

$\text{R}^9$  represents H, a lower alkyl, an aryl,  $-(\text{CO})\text{R}^{18a}$ ,  $-(\text{CS})\text{R}^{18a}$ ,  $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$ ,  
 $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$ ,  $-(\text{CO})\text{OR}^{20}$  or  $-(\text{CS})\text{OR}^{20}$  wherein  $\text{R}^{18a}$ ,  $\text{R}^{19a}$  and  $\text{R}^{20}$  are as defined above;

$\text{R}^{10}$  represents H, a lower alkyl or an aryl;

$\text{R}^{11}$  represents H, a lower alkyl or an aryl;

$\text{R}^{12}$  represents H, a lower alkyl, an aryl,  $-(\text{CO})\text{R}^{18a}$ ,  $-(\text{CS})\text{R}^{18a}$ ,  $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$ ,  
 $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$ ,  $-(\text{CO})\text{OR}^{20}$  or  $-(\text{CS})\text{OR}^{20}$  wherein  $\text{R}^{18a}$ ,  $\text{R}^{19a}$  and  $\text{R}^{20}$  are as defined above, or  
a substituent represented by the following general formula (6):




wherein  $s^+$  represents 1 to 6;

$\text{Y}^3$  represents O or S,

$\text{R}^{26}$  represents H, a lower alkyl or an aryl;

$\text{R}^{27}$  represents H, a lower alkyl, an aryl,  $-\text{OR}^{18a}$ ,  $-(\text{CO})\text{R}^{18a}$ ,  $-(\text{CS})\text{R}^{18a}$ ,  $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$ ,  
 $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$ ,  $-(\text{CO})\text{OR}^{20}$  or  $-(\text{CS})\text{OR}^{20}$  wherein  $\text{R}^{18a}$ ,  $\text{R}^{19a}$  and  $\text{R}^{20}$  are as defined above;

or  $\text{R}^{11}$  and  $\text{R}^{12}$  form a substituent represented by the following general formula (7) together  
with the nitrogen atom:



wherein  $Y^3$  represents O or S, and  $R^{27}$  is as defined above.

Claim 2 (currently amended): A compound ~~Diarylalkene derivatives or diarylalkane derivatives,~~ or pharmaceutically acceptable salts salt according to claim 1, wherein: ~~in the above general formulae (1), (2), (3) and (4), the group represented by V-W is C=C, CH-CH or N-CH;~~

~~Z is selected from the group consisting of C, CH and N (with the proviso that when Z is C, the bond represented by a dotted line represents a double bond and when Z is CH or N, the bond represented by the dotted line represents a single bond);~~

B represents  $NR^{17a}$ ,  $CHR^{21}$  and  $CH_2CHR^{21}$  wherein  $R^{17a}$  represents H, a lower alkyl or an aryl,  $R^{21}$  represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl,  $-CH_2SH$ ,  $-CH_2CH_2SCH_3$ ,  $-CH_2(CO)NH_2$ ,  $-CH_2CH_2(CO)NH_2$ ,  $-CH_2COOH$ ,  $-CH_2CH_2COOH$ ,  $-(CH_2)_4NH_2$ ,  $-(CH_2)_3NHC(NH_2)=NH$ , benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazoymethyl; and

$R^{18a}$  represents H, a lower alkyl or an aryl, and  $R^{19a}$  represents H, a lower alkyl or aryl; or  $R^{18a}$  and  $R^{19a}$  together form a cycloalkyl group which may have a halogen,  $-CF_3$ , a lower alkyl or an aryl as a substituent, and  $R^{25}$  and  $R^{27}$  ~~each represent~~ represents H, a lower alkyl, an aryl,  $-(CO)R^{18a}$ ,  $-(CS)R^{18a}$ ,  $-(CO)NR^{18a}R^{19a}$ ,  $-(CS)NR^{18a}R^{19a}$ ,  $-(CO)OR^{20}$  or  $-(CS)OR^{20}$ .

Claim 3 (currently amended): ~~A compound Diarylalkene derivatives or diarylalkane derivatives,~~ or pharmaceutically acceptable ~~salts~~ salt according to claim 2, wherein: ~~in the above general formulae (1), (2), (3) and (4),~~

~~A represents  $\text{CH}=\text{CH}$ ,  $\text{CH}_2-\text{CH}_2$ ,  $\text{S}$ ,  $\text{CH}_2-\text{S}$  or  $\text{S}-\text{CH}_2$ ;~~

a, b, c and d each represent CH;

$\text{R}^3$  and  $\text{R}^4$  each represent hydrogen atom;

$\text{R}^5$  and  $\text{R}^6$  each represent hydrogen atom;

or  $\text{R}^5$  and  $\text{R}^6$  together form  $=\text{O}$ ;

n represents 1 or 2;

$\text{Y}^1$  represents O;


B represents  $\text{NR}^{17a}$ ,  $\text{CHR}^{21}$  - or,  $\text{CH}_2\text{CHR}^{21}$  wherein  $\text{R}^{21}$  represents H, a lower alkyl, an aryl or  $-\text{CH}_2\text{OH}$ ;

G represents  $-(\text{CO})-$  or a covalent bond;

m represents 0 to 6;

p and q are each 1;

$\text{R}^7$  and  $\text{R}^8$  each independently represent H, a lower alkyl, an aryl,  $-(\text{CO})\text{R}^{18a}$  wherein  $\text{R}^{18a}$  represents H, a lower alkyl or an aryl,  $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$  wherein  $\text{R}^{19a}$  represents H, a lower alkyl or an aryl; or  $\text{R}^{18a}$  and  $\text{R}^{19a}$  together form a cycloalkyl which may have a halogen,  $-\text{CF}_3$ , a lower alkyl or an aryl as a substituent,  $-(\text{CO})\text{OR}^{20}$  wherein  $\text{R}^{20}$  represents an alkyl group having 1 to 12 carbon atoms, an aryl group or a cycloalkyl group which may contain a hetero atom in the ring, or a group of the following general formula (8):



~~{wherein~~ wherein  $Y^4$  and  $Y^3$  each represent O;

$s$  represents 1 or 2;

$E$  represents  $CHR^{23}$  wherein  $R^{23}$  represents H,

$R^{24}$  represents H;


$R^{25}$  represents  $-(CO)OR^{20}$ ; ~~;~~  $-(CO)OR^{20}$ ;

$R^9$  represents  $-(CO)OR^{20}[[;]]$

~~$R^{10}$  represents H;~~

~~$R^{11}$  represents H;~~

~~$R^{12}$  represents a substituent represented by the following general formula (9);~~




~~wherein  $s^+$  represents 2 or 3;~~

~~$Y^3$  represents O;~~

~~$R^{26}$  represents H;~~

~~and  $R^{27}$  represents  $-(CO)OR^{20}$ ;~~

or  $R^{11}$  and  $R^{12}$  form a substituent represented by the following general formula (10) together with the nitrogen atom:



wherein  $Y^3$  and  $R^{27}$  are as defined above.

Claim 4 (withdrawn-currently amended): A compound ~~Diarylalkene derivatives or diarylalkane derivatives~~, or pharmaceutically acceptable salts thereof salt according to claim 3, wherein: ~~in the above general formulae (1), (2), (3) and (4), A represents  $CH=CH$  or  $CH_2-CH_2$ ,~~

a, b, c and d each represent CH;

$R^1$  and  $R^2$  each represent H;

$R^3$  and  $R^4$  each represent H;

~~V-W represents  $C=C$ ;~~

n represents 2;

$R^5$  and  $R^6$  each represent H; and

$Y^1$  represents O.

Claim 5 (currently amended): A compound ~~Diarylalkene derivatives or diarylalkane derivatives~~, or pharmaceutically acceptable salts thereof salt according to claim 1, wherein: ~~in the above general formulae (1), (2), (3) and (4),~~



~~V-W represents C=C, CH-CH or N-CH;~~

~~Z is selected from the group consisting of C, CH and N (with the proviso that when Z is C, the bond represented by a dotted line represents a double bond and when Z is CH or N, the bond represented by the dotted line represents a single bond);~~

B represents  $-(CH_2)_v-CHR^{21}$  wherein v represents 2 or 3,  $R^{21}$  represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl,  $-CH_2SH$ ,  $-CH_2CH_2SCH_3$ ,  $-CH_2(CO)NH_2$ ,  $-CH_2CH_2(CO)NH_2$ , benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl; and  $R^{18a}$  represents H, a lower alkyl or an aryl, and  $R^{19a}$  represents H, a lower alkyl or aryl; or  $R^{18a}$  and  $R^{19a}$  together form a cycloalkyl group which may have a halogen,  $-CF_3$ , a lower alkyl or an aryl as a substituent.

Claim 6 (withdrawn-currently amended): A compound ~~Diarylalkene derivatives or diarylalkane derivatives,~~ or pharmaceutically acceptable salts thereof salt according to claim 5, wherein: ~~in the above general formula (1),~~

~~A represents CH=CH or CH<sub>2</sub>-CH<sub>2</sub>;~~

a, b, c and d each represent CH;

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  each represent H;

~~V-W represents C=C;~~

m represents 0 and n represents 2;


$Y^1$  represents O[[,]];

G represents a covalent bond[[,]]; and

$R^7$  and  $R^8$  each independently represent H, a lower alkyl,  $-(CO)R^{18a}$  wherein  $R^{18a}$  represents H, a lower alkyl or an aryl,  $-(CO)OR^{20}$  wherein  $R^{20}$  represents an alkyl group having 1 to 12 carbon atoms or an aryl.

Claim 7 (canceled).

Claim 8 (currently amended): A compound ~~Diarylalkene derivatives or diarylalkane derivatives of the following general~~ formula (1-A), or a pharmaceutically acceptable salts salt thereof:



wherein A represents ~~-CH=CH-, -CH<sub>2</sub>-CH<sub>2</sub>- or -S-~~;

B represents  $-(CH_2)_v-CHR^{21}$  wherein v represents 0 to 3,  $R^{21}$  represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl,  $-(CH_2)_w-COOR^{29}$  or  $-(CH_2)_w-NR^{29}R^{30}$  wherein  $R^{29}$  and  $R^{30}$  each independently represent hydrogen atom or a lower alkyl group and w represents 0 to 4;

G represents  $-(CO)-$  or a covalent bond;

m represents 0 to 6; and

$R^7$  and  $R^8$  each independently represent H, a lower alkyl, an aryl,  $-(CO)R^{18a}$  wherein  $R^{18a}$  represents H, a lower alkyl, an aryl or a cycloalkyl group which may contain a hetero atom in the ring, or  $-(CO)OR^{20}$  wherein  $R^{20}$  represents an alkyl group having 1 to 12 carbon atoms, an aryl or a cycloalkyl group which may have a hetero atom in the ring.

Claims 9-11 (canceled).

Claim 12 (withdrawn-currently amended): ~~A~~ The method for treating diseases a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs ~~according to claim 11~~, which method comprises ~~administering the diarylalkene derivative or diarylalkane derivative of the general formula (1), (2), (3) or (4),~~ administering an effective amount of at least one compound or pharmaceutically acceptable salt thereof, as the active ingredient to a patient in need of such treatment:

~~wherein the group represented by V-W is C=C, CH-CH or N-CH;~~

~~Z is selected from the group consisting of C, CH and N (with the proviso that when Z is C, the bond represented by a dotted line represents a double bond and when Z is CH or N, the bond represented by the dotted line represents a single bond);~~

~~B represents  $\text{NR}^{17a}$ ,  $\text{CHR}^{21}$  or  $\text{CH}_2\text{CHR}^{21}$  wherein  $\text{R}^{17a}$  represents H, a lower alkyl or an aryl,~~

~~$\text{R}^{21}$  represents H, a lower alkyl, an aryl, a hydroxyl lower alkyl,  $\text{CH}_2\text{SH}$ ,  $\text{CH}_2\text{CH}_2\text{SCH}_3$ ,~~

~~$\text{CH}_2(\text{CO})\text{NH}_2$ ,  $\text{CH}_2\text{CH}_2(\text{CO})\text{NH}_2$ ,  $\text{CH}_2\text{COOH}$ ,  $\text{CH}_2\text{CH}_2\text{COOH}$ ,  $(\text{CH}_2)_4\text{NH}_2$ ,~~

~~$(\text{CH}_2)_3\text{NHC}(\text{NH}_2)=\text{NH}$ , benzyl, 4-hydroxybenzyl, 3-indoymethyl or 5-imidazolymethyl; and~~

~~$\text{R}^{18a}$  represents H, a lower alkyl or an aryl, and  $\text{R}^{19a}$  represents H, a lower alkyl or an aryl; or~~

~~$\text{R}^{18a}$  and  $\text{R}^{19a}$  together form a cycloalkyl group which may have a halogen,  $\text{CF}_3$ , a lower alkyl~~

~~or an aryl as a substituent, and  $\text{R}^{25}$  and  $\text{R}^{27}$  each represent H, a lower alkyl, an aryl,  $(\text{CO})\text{R}^{18a}$ ,~~

~~$(\text{CS})\text{R}^{18a}$ ,  $(\text{CO})\text{NR}^{18a}\text{R}^{19a}$ ,  $(\text{CS})\text{NR}^{18a}\text{R}^{19a}$ ,  $(\text{CO})\text{OR}^{20}$  or  $(\text{CS})\text{OR}^{20}$  according to claim 1 to~~

a patient in need of such treatment.

Claim 13 (withdrawn-currently amended): A method for treating ~~diseases~~ a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises ~~administering the diarylalkene derivative or diarylalkane derivative,~~ administering an effective amount of at least one compound or pharmaceutically acceptable salt thereof according to claim 2 ~~as the active ingredient~~ to a patient in need of such treatment.

Claim 14 (withdrawn-currently amended): A method for treating ~~diseases~~ a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises ~~administering the diarylalkene derivative or diarylalkane derivative,~~ administering an effective amount of at least compound or pharmaceutically acceptable salt thereof according to claim 3 ~~5 as the active ingredient~~ to a patient in need of such treatment.

Claim 15 (withdrawn-currently amended): A method for treating ~~diseases~~ a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head

injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises ~~administering the diarylalkene derivative or diarylalkane derivative,~~ administering an effective amount of at least compound or pharmaceutically acceptable salt thereof according to claim ~~4~~ 7 as the active ingredient to a patient in need of such treatment.

Claim 16 (withdrawn-currently amended): A method for treating ~~diseases~~ a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises ~~administering the diarylalkene derivative or diarylalkane derivative,~~ administering an effective amount of at least one compound or pharmaceutically acceptable salt thereof according to claim ~~5~~ 8 as the active ingredient to a patient in need of such treatment.

Claim 17 (withdrawn-currently amended): A method for treating ~~diseases~~ a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises ~~administering the diarylalkene derivative or diarylalkane derivative,~~ administering an effective amount of at least one compound or pharmaceutically acceptable salt thereof according to claim ~~6~~ 9 as the active ingredient to a patient in need of such treatment.

Claim 18 (withdrawn-currently amended): A method for treating ~~diseases~~ a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises ~~administering the diarylalkene derivative or diarylalkane derivative,~~ administering an effective amount of at least one compound or pharmaceutically acceptable salt thereof according to claim ~~8~~ 10 ~~as the active ingredient~~ to a patient in need of such treatment.

Claim 19 (withdrawn-currently amended): A method for antagonizing N-type calcium channels, which method comprises ~~administering the diarylalkene derivatives or diarylalkane derivatives,~~ administering an effective amount of at least one compound or pharmaceutically acceptable salts thereof salt according to claim ~~1~~ 11 ~~as the active ingredient~~ to a patient in need of such antagonistic action.

Claim 20 (currently amended): A pharmaceutical composition comprising ~~the diarylalkene derivatives or diarylalkane derivatives,~~ at least one compound or pharmaceutically acceptable salts thereof salt according to claim 1 ~~as the active ingredient,~~ and at least one pharmaceutically acceptable adjuvants adjuvant.

Claim 21 (currently amended): A pharmaceutical composition comprising at least one of the diarylalkene derivatives, diarylalkane derivatives and compound or

pharmaceutically acceptable salts thereof salt according to claim 2 ~~as the active ingredient,~~  
and at least one pharmaceutically acceptable ~~adjuvants~~ adjuvant.

Claim 22 (currently amended): A pharmaceutical composition comprising at least  
~~one of the diarylalkene derivatives, diarylalkane derivatives and~~ compound or  
pharmaceutically acceptable salts thereof salt according to claim 3 ~~5 as the active ingredient,~~  
and at least one pharmaceutically acceptable ~~adjuvants~~ adjuvant.

Claim 23 (withdrawn-currently amended): A pharmaceutical composition  
comprising at least ~~one of the diarylalkene derivatives, diarylalkane derivatives and~~  
compound or pharmaceutically acceptable salts thereof salt according to claim 4 ~~7 as the~~  
~~active ingredient,~~ and at least one pharmaceutically acceptable ~~adjuvants~~ adjuvant.


Claim 24 (currently amended): A pharmaceutical composition comprising at least  
~~one of the diarylalkene derivatives, diarylalkane derivatives and~~ compound or  
pharmaceutically acceptable salts thereof salt according to claim 5 ~~8 as the active ingredient,~~  
and at least one pharmaceutically acceptable ~~adjuvants~~ adjuvant.

Claim 25 (withdrawn-currently amended): A pharmaceutical composition  
comprising at least ~~one of the diarylalkene derivatives, diarylalkane derivatives and~~  
compound or pharmaceutically acceptable salts thereof salt according to claim 6 ~~9 as the~~  
~~active ingredient,~~ and at least one ~~at least one~~ pharmaceutically acceptable ~~adjuvants~~ adjuvant.

Claim 26 (currently amended): A pharmaceutical composition comprising at least  
~~one of the diarylalkene derivatives, diarylalkane derivatives and~~ compound or


pharmaceutically acceptable salts thereof salt according to claim ~~8~~ 10 as the active ingredient,  
and at least one pharmaceutically acceptable ~~adjuvants~~ adjuvant.

Claim 27 (new): A compound having the formula:



or a pharmaceutically acceptable salt thereof.


Claim 28 (new): A compound having the formula:



or a pharmaceutically acceptable salt thereof.




Claim 29 (new): A compound having the formula:



or a pharmaceutically acceptable salt thereof.

Claim 30 (new): A compound having the formula:



or a pharmaceutically acceptable salt thereof.

Claim 31 (new): A method for treating a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises administering an effective amount of at least one compound or pharmaceutically acceptable salt according to claim 27 to a patient in need of such treatment.

Claim 32 (new): A method for treating a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises administering an effective amount of at least one compound or pharmaceutically acceptable salt according to claim 28 to a patient in need of such treatment.

Claim 33 (new): A method for treating a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises administering an effective amount of at least one compound or pharmaceutically acceptable salt according to claim 29 to a patient in need of such treatment.

Claim 34 (new): A method for treating a disease selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which method comprises administering an effective amount of at least one compound or pharmaceutically acceptable salt according to claim 30 to a patient in need of such treatment.

Claim 35 (new): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 27 and at least one pharmaceutically acceptable adjuvant.

Claim 36 (new): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 28 and at least one pharmaceutically acceptable adjuvant.

Claim 37 (new): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 29 and at least one pharmaceutically acceptable adjuvant.

Claim 38 (new): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 30 and at least one pharmaceutically acceptable adjuvant.